WO2021237149A3 - Treatment of non-alcoholic steatohepatitis (nash) - Google Patents

Treatment of non-alcoholic steatohepatitis (nash) Download PDF

Info

Publication number
WO2021237149A3
WO2021237149A3 PCT/US2021/033749 US2021033749W WO2021237149A3 WO 2021237149 A3 WO2021237149 A3 WO 2021237149A3 US 2021033749 W US2021033749 W US 2021033749W WO 2021237149 A3 WO2021237149 A3 WO 2021237149A3
Authority
WO
WIPO (PCT)
Prior art keywords
nash
alcoholic steatohepatitis
treatment
methods
25hc3s
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2021/033749
Other languages
French (fr)
Other versions
WO2021237149A2 (en
Inventor
Weiqi Lin
James E. Brown
Terrence BLASCHKE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Durect Corp
Original Assignee
Durect Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Durect Corp filed Critical Durect Corp
Publication of WO2021237149A2 publication Critical patent/WO2021237149A2/en
Publication of WO2021237149A3 publication Critical patent/WO2021237149A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

Methods of treating non-alcoholic steatohepatitis (NASH) are provided. For instance, the methods comprise administering 5-cholesten-3,25-diol, 3-sulfate (25HC3S) or a salt thereof.
PCT/US2021/033749 2020-05-22 2021-05-21 Treatment of non-alcoholic steatohepatitis (nash) Ceased WO2021237149A2 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US202063029366P 2020-05-22 2020-05-22
US63/029,366 2020-05-22
US202063030219P 2020-05-26 2020-05-26
US63/030,219 2020-05-26
US202063113115P 2020-11-12 2020-11-12
US63/113,115 2020-11-12
US202163146557P 2021-02-05 2021-02-05
US63/146,557 2021-02-05

Publications (2)

Publication Number Publication Date
WO2021237149A2 WO2021237149A2 (en) 2021-11-25
WO2021237149A3 true WO2021237149A3 (en) 2021-12-30

Family

ID=78718209

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/033749 Ceased WO2021237149A2 (en) 2020-05-22 2021-05-21 Treatment of non-alcoholic steatohepatitis (nash)

Country Status (2)

Country Link
TW (1) TW202214256A (en)
WO (1) WO2021237149A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9034859B2 (en) * 2011-04-06 2015-05-19 Virginia Commonwealth University Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9034859B2 (en) * 2011-04-06 2015-05-19 Virginia Commonwealth University Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ATHYROS ET AL.: "The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement", METABOLISM CLINICAL AND EXPERIMENTAL, vol. 71, 2017, pages 17 - 32, XP085023393, DOI: 10.1016/j.metabol.2017.02.014 *
KIYICI ET AL.: "Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis", CAN J GASTROENTEROL., vol. 17, no. 12, 2003, pages 713 - 718, XP055881114, DOI: 10.1155/2003/857869 *

Also Published As

Publication number Publication date
TW202214256A (en) 2022-04-16
WO2021237149A2 (en) 2021-11-25

Similar Documents

Publication Publication Date Title
MX2022014574A (en) Treatment of non-alcoholic steatohepatitis (nash).
MX2022014575A (en) Treatment of non-alcoholic steatohepatitis (nash).
MX2022013163A (en) Antibody against nectin-4 and application thereof.
PH12022550698A1 (en) Treatment of alcoholic hepatitis
MX2023011145A (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer.
BR112021011684A2 (en) Combination Therapy With CD70 and Venetoclax, a Bcl-2 Inhibitor, for the Treatment of Acute Myeloid Leukemia
MX2021005075A (en) Methods for treating castration-resistant and castration- sensitive prostate cancer.
EP4588484A3 (en) Methods of treating multiple myeloma
MX2009009636A (en) Methods of treating ophthalmic diseases.
AU2017269839A1 (en) Methods for treatment of refractory generalized myasthenia gravis
MX2009009816A (en) Monoclonal antibodies for treatment of cancer.
CR20230128A (en) Anti-nectin-4 antibody, conjugate including same, and application thereof
EP4316517A3 (en) Combination therapy against cancer
EP4438124A3 (en) Methods for treating testicular and ovarian adrenal rest tumors
MX2024012292A (en) Improved diagnosis of nonalcoholic steatohepatitis
MX2024003952A (en) Combination comprising atogepant for treating migraine.
WO2019053613A3 (en) Combination treatment for cancer
WO2024077023A3 (en) Cereblon-recruiting bcl-xl/bcl-2 dual degraders
PH12022552725A1 (en) Anti-ox40 antibody and uses thereof
WO2021257816A3 (en) Modified caveolin-1 peptides for the treatment of pathogen-induced lung injury
WO2019224385A3 (en) Combined bispecific antibody and immuno-oncology therapies
MX2020009349A (en) Method for treating post-prandial hypoglycemia.
EA202092540A1 (en) COMBINATIONS FOR CANCER TREATMENT
PH12021552499A1 (en) Methods for the treatment of beta-thalassemia
WO2021102359A3 (en) Taspase1 inhibitors and uses thereof

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21807965

Country of ref document: EP

Kind code of ref document: A2